✦ LIBER ✦

Surrogate Versus Clinical End Points and Venture Capital Companies: The Doubts of a Clinician

✍ Scribed by Antonio V. Gaddi; Danilo Benedetto

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In Reply to ‘Discounting the Efficacy of

✍ Matthew A. Weir; Andrew A. House 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 143 KB

The validation of surrogate end points b

✍ Tomasz Burzykowski; Geert Molenberghs; Marc Buyse 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB